Search Results

  • Why Allergan is Not the Next Valeant

    Published: July 07, 2016

    In the aftermath of Brexit, many investors have forgotten about the continuing shakeup in pharmaceuticals. The S&P Pharmaceuticals Select Industry Index has fallen by 28% in the last year, with prominent hedge funds losing particularly big on much-hyped Valeant (VRX:CN). According to SumZero cont...

    Read More »

  • Funds Face Off on Valeant

    Two of SumZero’s most successful and outspoken members, Navi Hehar of Mile 26 Capital in New York and David Trainer of Novo Capital in Nashville, came down on opposite sides of one of the most talked about stocks of the year, Valeant Pharmaceuticals. With highly publicized investigations by the S...

    Read More »